Insertional oncogenesis in gene therapy: how much of a risk?
about
Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B miceCardiovascular gene therapy for myocardial infarctionAdoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma modelSingle Cell-Based Vector Tracing in Patients with ADA-SCID Treated with Stem Cell Gene Therapy.Globin gene transfer as a potential treatment for the beta-thalassaemias and sickle cell disease.Making a Hematopoietic Stem CellA Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.Investigational agents for sickle cell disease.Genetic therapies against HIV.The Functionality of Minimal PiggyBac Transposons in Mammalian Cells.Antibody-modified T cells: CARs take the front seat for hematologic malignancies.The Oncogenic Potential of Mesenchymal Stem Cells in the Treatment of Cancer: Directions for Future Research.Gene therapy for β-thalassaemia: the continuing challenge.Fetal gene therapy: recent advances and current challenges.Ocular gene delivery using lentiviral vectors.Changing blue fluorescent protein to green fluorescent protein using chemical RNA editing as a novel strategy in genetic restoration.Recombinase mediated cassette exchange into genomic targets using an adenovirus vector.Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression.A method to estimate the efficiency of gene expression from an integrated retroviral vector.Stem cell-derived erythroid cells mediate long-term systemic protein delivery.Development of a Cell-Based Gene Therapy Approach to Selectively Turn Off Bone Formation.Developments in Hematopoietic Stem Cell Expansion and Gene Editing Technologies.Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery.Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
P2860
Q24654670-D67449F7-435B-46E8-96E9-B3388BD9BE6FQ27014770-1A291BB9-EDB9-4E40-8896-A3DBFC520449Q30437670-E041BB83-270D-44BA-940A-DCB255001510Q33784306-DCC60F9E-C4EB-4103-9D14-E5E5E54A336BQ35813119-26514C07-E10E-478D-A3DF-C7AE1BB3CA25Q35829658-19083F9E-2522-49AE-9E1D-B1E9930549F3Q36043637-F456CBC0-132F-45B0-89B6-8D998E10733CQ36543049-7C498C3C-2B32-4B09-8A37-5D45DEE4C01CQ37027170-26D92E1E-8EFE-496A-A49C-3ADE285904DEQ37393970-C55A816E-C8FD-49C4-8813-417EBC38B151Q37723469-72747A31-CD93-48EC-B681-5EE725DC77DCQ37758303-D1F5EDC6-9AAC-4CA8-8AF8-E067E7C2FA8CQ37795125-4D05465D-39FC-4E07-81B8-CB6729494EF3Q37881971-B35BC00C-2DAF-4BC1-9344-8C0377660A65Q37952564-DC3B31EE-BFA6-4937-93BE-6293F20856F3Q39000784-D7C35089-8942-4B80-9355-4BC9FA49E743Q39718303-A2A0B97F-F69E-43BA-8A31-A79B2543AB04Q41494111-17B2F6D4-FE9A-42CD-8BC0-511ED1087398Q42118383-6589E42F-F768-4A4B-AE2A-11D6384EF2A7Q43249231-737D184C-9B99-4718-B8B4-8EE34A161724Q45861150-9D4FE99C-F85B-42E2-81BF-40E7A6154C0DQ45868902-5FF9A64B-13E9-49BC-AE31-3527FBB37559Q47438268-0D1C8AB8-B4AE-4218-BCB6-5B66492CCA2EQ52726716-D03B1C3E-87A3-4F59-A178-1A4E602B877EQ53705286-16BBED1B-0D3F-47F3-9BF7-81194B6069FD
P2860
Insertional oncogenesis in gene therapy: how much of a risk?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Insertional oncogenesis in gene therapy: how much of a risk?
@en
Insertional oncogenesis in gene therapy: how much of a risk?
@nl
type
label
Insertional oncogenesis in gene therapy: how much of a risk?
@en
Insertional oncogenesis in gene therapy: how much of a risk?
@nl
prefLabel
Insertional oncogenesis in gene therapy: how much of a risk?
@en
Insertional oncogenesis in gene therapy: how much of a risk?
@nl
P2860
P356
P1433
P1476
Insertional oncogenesis in gene therapy: how much of a risk?
@en
P2093
Sadelain M
P2860
P2888
P304
P356
10.1038/SJ.GT.3302243
P577
2004-04-01T00:00:00Z
P5875
P6179
1047354190